Search results for "adverse effects"

showing 10 items of 82 documents

Intracerebral Hemorrhage and Outcome After Thrombolysis in Stroke Patients Using Selective Serotonin-Reuptake Inhibitors.

2017

Background and Purpose— Selective serotonin-reuptake inhibitors (SSRIs) impair platelet function and have been linked to a higher risk of spontaneous intracerebral hemorrhage—an association that may be augmented by oral anticoagulants (OAC). We aimed to assess whether preadmission treatment with SSRIs in patients with acute ischemic stroke is associated with post-thrombolysis symptomatic intracerebral hemorrhage (sICH) and functional outcome. Methods— A multicenter retrospective analysis was conducted in prospective registries of patients treated by thrombolysis within 4.5 hours of stroke onset. The association between preadmission treatment with SSRIs and sICH (ECASS II definition [Europe…

Malemedicine.medical_specialtytherapeutic use [Anticoagulants]medicine.medical_treatmentSubgroup analysisepidemiology [Cerebral Hemorrhage]Risk AssessmentCohort Studies03 medical and health sciencesadverse effects [Serotonin Uptake Inhibitors]0302 clinical medicineModified Rankin ScaleInternal medicinemedicineHumansThrombolytic Therapy030212 general & internal medicineddc:610610 Medicine & healthStrokeCerebral HemorrhageAgedRetrospective StudiesAdvanced and Specialized NursingIntracerebral hemorrhageAged 80 and overtherapy [Cerebral Hemorrhage]business.industryAnticoagulantsThrombolysisOdds ratioMiddle Agedmedicine.diseaseadverse effects [Selective Serotonin Reuptake Inhibitors]Prognosisdrug therapy [Stroke]StrokeTreatment OutcomeAnesthesiaConcomitantSerotonin Uptake InhibitorsFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerySelective Serotonin Reuptake Inhibitorsepidemiology [Stroke]Cohort study
researchProduct

Safety of endovascular treatment in acute stroke patients taking oral anticoagulants

2017

International journal of stroke 12(4), 412-415 (2017). doi:10.1177/1747493016677986

Maletherapeutic use [Anticoagulants]medicine.medical_specialtyMedizinAdministration Oral030204 cardiovascular system & hematologyBrain IschemiaBrain ischemia03 medical and health sciences0302 clinical medicineetiology [Intracranial Hemorrhages]Modified Rankin ScaleInterquartile rangeAntithromboticmedicineHumansThrombolytic Therapyddc:610Prospective StudiesRegistriesadverse effects [Anticoagulants]Prospective cohort studyStrokeAgedAged 80 and overbusiness.industryConfoundingAnticoagulantsmethods [Thrombolytic Therapy]complications [Brain Ischemia]Middle Agedmedicine.diseasedrug therapy [Stroke]Surgerysurgery [Stroke]StrokeTreatment Outcomeadministration & dosage [Anticoagulants]Neurologydrug therapy [Brain Ischemia]FemaleObservational studydrug therapy [Intracranial Hemorrhages]businessIntracranial Hemorrhages030217 neurology & neurosurgery
researchProduct

A time series study on the effects of heat on mortality and evaluation of heterogeneity into European and Eastern-Southern Mediterranean cities: resu…

2013

Background: The Mediterranean region is particularly vulnerable to the effect of summer temperature. Within the CIRCE project this time-series study aims to quantify for the first time the effect of summer temperature in Eastern-Southern Mediterranean cities and compared it with European cities around the Mediterranean basin, evaluating city characteristics that explain between-city heterogeneity. Methods: The city-specific effect of maximum apparent temperature (Tappmax) was assessed by Generalized Estimation Equations, assuming a linear threshold model. Then, city-specific estimates were included in a random effect meta-regression analysis to investigate the effect modification by several…

Mediterranean climateMaleMESH: Urban HealthHot TemperatureTime FactorsClimateHealth Toxicology and MutagenesisVulnerability010501 environmental sciences01 natural sciencesMediterranean BasinMESH: Regression AnalysisMESH: Cause of Death0302 clinical medicineAfrica NorthernMESH: ChildCause of Death11. Sustainability030212 general & internal medicineMediterranean regionSocioeconomicsChildMESH: Aged[SDV.EE]Life Sciences [q-bio]/Ecology environmentMiddle EastMESH: Middle AgedMESH: Infant Newborn1. No povertyAge FactorsMiddle AgedMESH: ClimateMESH: Middle East/epidemiologyMESH: Infant3. Good healthGeographyMESH: Young AdultChild Preschool8. Economic growthRegression AnalysisFemaleSeasonsAdultmedicine.medical_specialtyAdolescentClimate changeHeat Stress DisordersMESH: Mediterranean Region/epidemiology03 medical and health sciencesMiddle EastYoung AdultmedicineMESH: CitiesHumansCitiesMortalityMESH: Heat Stress Disorders/mortality*0105 earth and related environmental sciencesMESH: Hot Temperature/adverse effectsAgedEstimationMESH: AdolescentMESH: Age FactorsMESH: Heat Stress Disorders/etiologyMESH: HumansPublic healthResearchMESH: Child PreschoolMESH: Time FactorsInfant NewbornUrban HealthPublic Health Environmental and Occupational HealthMESH: Africa Northern/epidemiologyInfantMESH: AdultMESH: MaleApparent temperature13. Climate actionHot temperature; Mortality; Mediterranean region; Heterogeneity; Age groups; Public Health; TIME series analysis; Older people; Public health; Unemployment statistics; Climatic changes[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Mortality/trends*HeterogeneityAge groupsMESH: FemaleMESH: SeasonsMedicine; Geriatrics
researchProduct

Short stem total hip arthroplasty: Potential explanations for persistent post-surgical thigh pain.

2017

Abstract: Short stem uncemented femoral implants were developed with the aim of preserving proximal bone stock for future revisions, improving biomechanical reconstruction, aiding insertion through smaller incisions and potentially decreasing or limiting the incidence of thigh pain. Despite all the advantages of short stem designs, it remains unclear whether they are able to limit post-surgical thigh pain. In patients with short stem hip arthroplasty and persistent thigh pain, it is of the utmost importance to understand the potential etiologies of this chronic pain for selecting the appropriate treatment strategy. Therefore, this manuscript explores the hypothetical etiologies of persisten…

Nervous systemBiopsychosocial modelmusculoskeletal diseasesCentral Nervous SystemReoperationmedicine.medical_specialtymedicine.medical_treatmentArthroplasty Replacement HipThighProsthesis DesignModels BiologicalNociceptive Pain03 medical and health sciences0302 clinical medicinemedicineHip Prosthesis/adverse effectsHumansNociceptive Pain/etiologyPain Postoperative/etiology030222 orthopedicsPain Postoperativebusiness.industryChronic painNociceptorsGeneral Medicinemedicine.diseaseArthroplastySurgeryBiomechanical Phenomenamedicine.anatomical_structureNociceptionArthroplasty Replacement Hip/adverse effectsThighCentral Nervous System/physiopathologyOrthopedic surgeryEtiologyPhysical therapyHuman medicineHip ProsthesisbusinessNociceptors/physiology030217 neurology & neurosurgeryMedical hypotheses
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort

2020

PURPOSE The HIT-2000-BIS4 trial aimed to avoid highly detrimental craniospinal irradiation (CSI) in children < 4 years of age with nonmetastatic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local radiotherapy. PATIENTS AND METHODS From 2001-2011, 87 patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for nonresponse or progression. After 2006, local radiotherapy was introduced for nonresponders or patients with classic medulloblastoma (CMB) or large-cell/anaplastic medulloblastoma (LCA). DNA methylation profiles of infantile sonic hedgehog-activated medulloblastoma (SHH-INF) were subdivided i…

OncologyMaleCancer ResearchMedizinradiotherapy [Medulloblastoma]Neuropsychological Testsadverse effects [Cranial Irradiation]Craniospinal Irradiation0302 clinical medicinemortality [Cerebellar Neoplasms]drug therapy [Medulloblastoma]Early childhoodProspective Studiesddc:618Systemic chemotherapyCerebellar Neoplasms / mortality3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolMedulloblastoma / radiotherapyFemalemortality [Medulloblastoma]medicine.medical_specialtyCerebellar Neoplasms / drug therapyCerebellar Neoplasms / radiotherapyMEDLINEMedulloblastoma / drug therapyadministration & dosage [Methotrexate]03 medical and health sciencesInternal medicinedrug therapy [Cerebellar Neoplasms]medicineHumansddc:610Cerebellar NeoplasmsMedulloblastomaCranial Irradiation / adverse effectsbusiness.industryEditorialsInfantMethotrexate / administration & dosageDNA Methylationmedicine.diseaseClinical trialMethotrexateMedulloblastoma / mortalityradiotherapy [Cerebellar Neoplasms]Cranial IrradiationbusinessValidation cohort030217 neurology & neurosurgeryMedulloblastoma
researchProduct

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

2012

Background: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and methods: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. Results: Median number of therapeutic li…

OncologyMaleLung NeoplasmsColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntibodieCetuximab; Clinical trial; Colorectal neoplasms; Phase II; RetreatmentDrug ResistanceCetuximabadverse effects/pharmacology/therapeutic useAdult; Aged; 80 and over; Antibodies; Monoclonal; administration /&/ dosage; Antineoplastic Combined Chemotherapy Protocols; adverse effects/pharmacology/therapeutic use; Camptothecin; administration /&/ dosage/analogs /&/ derivatives; Colorectal Neoplasms; drug therapy/mortality/pathology; Disease-Free Survival; Drug Resistance; Neoplasm; Exanthema; chemically induced; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; drug therapy/mortality/secondary; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment OutcomeColorectal NeoplasmKaplan-Meier EstimateAntineoplastic Combined Chemotherapy ProtocolsMonoclonal80 and overProspective cohort studyadministration /&/ dosageAged 80 and overCetuximabLiver NeoplasmsAntibodies MonoclonalHematologyMiddle AgedChemotherapy regimenPhase IIClinical trialTreatment OutcomeOncologyLiver NeoplasmLymphatic MetastasisRetreatmentchemically inducedFemaleColorectal Neoplasms/ dosage/analogs /&ampmedicine.drugHumanAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedIrinotecanAntibodiesDisease-Free SurvivalColorectal neoplasmdrug therapy/mortality/secondarySDG 3 - Good Health and Well-beingInternal medicineadministration /&/ dosage/analogs /&/ derivativesmedicine/ dosageHumansProgression-free survivalneoplasmsAgeddrug therapy/mortality/pathologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryLymphatic MetastasiExanthemamedicine.diseasedigestive system diseasesIrinotecanClinical trialLung Neoplasm/ derivativeDrug Resistance Neoplasmadministration /&ampNeoplasmCamptothecinbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

2014

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…

OncologyMaleNeurologyfingolimod multiple sclerosis treatment first dose safetyadministration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic useImmunosuppressive AgentSphingosineMultiple SclerosiAtrioventricular Blockadministration /&/ dosage/adverse effects/therapeutic useGeneral MedicineMiddle AgedTolerabilityPropylene GlycolFingolimoddrug therapyTolerabilityAnesthesiaCohortAdolescent Adult Atrioventricular Block; chemically induced/epidemiology Drug Therapy; Combination Female Humans Immunosuppressive Agents; administration /&/ dosage/adverse effects/therapeutic use Male Middle Aged Multiple Sclerosis; drug therapy Propylene Glycols; administration /&/ dosage/adverse effects/therapeutic use Sphingosine; administration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic use Young AdultCombinationDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAtrioventricular block; Bradycardia; Fingolimod; Multiple sclerosis; Safety; Tolerability; Adolescent; Adult; Atrioventricular Block; Drug Therapy Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult; Neurology (clinical)SafetyAtrioventricular block Bradicardia Multiple sclerosis Fingolimod Safety TolerabilityImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentClinical NeurologyYoung AdultFingolimod HydrochlorideInternal medicineBradycardiamedicineHumansNeurochemistryFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseClinical trialPropylene GlycolsAtrioventricular block Bradycardia Multiple sclerosis Fingolimod Safety Tolerabilitychemically induced/epidemiologyNeurology (clinical)business
researchProduct

Impact of universal vaccination against varicella in Italy: Experiences from eight Italian Regions.

2014

In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13-15 months and 5-6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with …

Pediatricsmedicine.medical_specialtyImmunologyadverse events following varicella immunizationVaricellaSettore MED/42 - Igiene Generale E ApplicataEnvironmental healthmedicineImmunology and AllergyHealth policyChickenpox VaccinePharmacologyChickenpoxbusiness.industryIncidence (epidemiology)immunization coverageHealth services researchUniversal Varicella VaccinationnotificationsVaricella; Universal Varicella Vaccination; Notifications; Hospitalizations; Immunization coverage; Adverse effectsmedicine.diseaseVaccinationImmunizationVaccination coverageUniversal Varicella Vaccination; Varicella; adverse events following varicella immunization; hospitalizations; immunization coverage; notificationsbusinesshospitalization
researchProduct

The type of GnRH analogue used during controlled ovarian stimulation influences early embryo developmental kinetics: a time-lapse study

2013

OBJECTIVE: To explore if the GnRH analogue used for controlled ovarian stimulation (COS) and the ovulation triggering factor (GnRH agonist + hCG triggering versus GnRH antagonist + GnRH agonist triggering) affect embryo development and kinetics.STUDY DESIGN: In a retrospective cohort study in the Instituto Valenciano de Infertilidad (IVI) Alicante and the Instituto Universitario-IVI Valencia, Spain, 2817 embryos deriving from 400 couples undergoing oocyte donation were analysed. After controlled ovarian stimulation and IVF/intracytoplamic sperm injection, the timing of embryonic cleavages was assessed by a video time-lapse system. The results were analysed using Student's t test for compari…

Pregnancy RateZygoteGonadotropin-Releasing Hormone/adverse effectsmedicine.medical_treatmentGonadotropin-releasing hormoneChorionic GonadotropinGonadotropin-Releasing HormoneEmbryo Culture TechniquesCohort StudiesTime-lapsePregnancyGnRH analogueFertility Agents Female/adverse effectsmedia_commonOocyte DonationObstetrics and GynecologyEmbryoEmbryo transferembryonic structuresSpain/epidemiologyEctogenesis/drug effectsFemaleInfertility Femalehormones hormone substitutes and hormone antagonistsEmbryo qualityAdultAgonistInfertility Female/therapyendocrine systemmedicine.medical_specialtymedicine.drug_classCleavage Stage Ovummedia_common.quotation_subjectFertilization in VitroBiologyTime-Lapse ImagingOvulation InductionInternal medicinemedicineHumansOvulationRetrospective StudiesZygote/drug effectsFertility Agents FemaleOvulation Induction/methodsEmbryo TransferEmbryo developmental kineticsKineticsPregnancy rateEndocrinologyReproductive MedicineSpainEctogenesisChorionic Gonadotropin/pharmacologyOvulation inductionCleavage Stage Ovum/drug effectsEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct